Product
metreleptin
Name
Myalept
INN Name
metreleptin
FDA Approved
Yes
1 clinical trial
2 organizations
1 indication
1 document
Indication
Partial LipodystrophyClinical trial
A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial LipodystrophyStatus: Recruiting, Estimated PCD: 2025-06-30
Document
DailyMed Label: MyaleptOrganization
Amryt Pharmaceuticals DACOrganization
Chiesi USA, Inc.